InvestorsHub Logo
Followers 51
Posts 9111
Boards Moderated 1
Alias Born 10/25/2007

Re: None

Tuesday, 04/18/2023 12:12:01 AM

Tuesday, April 18, 2023 12:12:01 AM

Post# of 13489
“The profound observed reduction in the risk of recurrence-free survival suggests this combination may be a novel means of potentially extending the lives of patients with high-risk melanoma,” said Kyle Holen, a senior vice president and head of development, therapeutics and oncology at Moderna.

Globally, we are on track-
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MRNA News